| Background and ObjectivesGuillain-Barre Syndrome(GBS) is an autoimmune peripheral neuropathy,with both celluar and humoral immune response taking part in its pathogenesis,and it is an important cause of acute neuromuscular paralysis.A number of inflammatory cytokines are found to play very important roles in initiating,enhancing and perpetuating pathlhysiological procedure in GBS.In recent years,more and more studies about the relationship of cytokine and Guillain-Barre Syndrome appear.A great deal of studies consider that pro-inflammatory and anti-inflammatory cytokines are determing the development and the results of the disease by changing the differentiation and the generation of Thl and Th2 cells.Thl7 cells have recently emerged as a third independent CD4(+)T cell submet,in recent years,the function of Th17 cells have become one of the hot spot area of immunity, as a member of Th17 cell factor family,IL-17 plays significant action as a pro-inflammatory cytokine.IL-35 is a member of IL-12 family,which was found as an anti-inflammatory cytokine, plays it’s function by stimulating the proliferation of regulatory T cells.In this research,we aimed to discuss the function of IL-17 and IL-35 in GBS as well as their association with the clinical pattern and severity of GBS by testing the serum concentration of IL-17 and IL-35 during the different stages of GBS.On the other side,we want to explore new theoretical basis for the treatment of GBS.Resource and Methods56 patients with GBS were enrolled in the study in the neurology department of the first affiliated hospital of ZhengZhou University from June in 2010 to march in 2012,there are 33 males and 23 females,average age is (38.27±14.91) years,range from 12 to 63 years.All GBS patients were diagnosed according to the diagnostic criteria established by Asbury etc,all of them received specialized examination of nervous system,electrophysiological examination and cerebrospinal fluid examination,and all GBS patients were graded on Hughes.Thirty-seven healthy volunteers constituted the control group,there are 19 males and 18 females,average age is (37.62±14.51) years,range from 13 to 67 years,all of them were eliminated the history of precedent infection,allergic diseases and autoimmune disease.All the subjects are drown venous blood 3ml from elbow,and all the serum species were preserved at the temperature of-80℃.The group of GBS patients were drown venous blood druing the acute phase and the recovery phase respectively.We measure the serum level of IL-17 and IL-35 through ELISA.Statistic analyses were performed with the SPSS 17.0.Measurement data were expressed by (x±s),value were considered statistically significant at P<0.05.Resultse1.The concentration of IL-17 in serum both in the acute (431.82±85.86)pg/ml and recovery (366.80±66.54)pg/ml phase of GBS patients are elevated significantly compared to the healthy control (244.39±47.78)pg/ml groups,while the serum level of IL-17 are up-regulated more significantly during the acute stage than the recovery stage.2.The concentration of IL-35 in serum both in the acute (42.18±9.62)ng/ml and recovery (52.89±12.16)ng/ml phase of GBS patients are elevated significantly compared to the healthy control (36.04±8.31)ng/ml groups,while the serum level of IL-35 are up-regulated more significantly during the recovery stage than the acute stage.3.The serious subgroup (466.55±102.01)pg/ml of GBS patients shows higher serum level of IL-17 during the acute phase than the mild subgroup (413.99±71.39)pg/ml. However, the concentration of IL-35 in serum shows no significant difference between the serious subgroup (38.82±8.54)ng/ml and mild subgroup (43.91±9.79)ng/ml of GBS.4.The serious subgroup (397.74±59.96)pg/ml of GBS patients shows higher serum level of IL-17 during the recovery phase than the mild subgroup (350.91±64.82)pg/ml. The mild subgroup (55.26±12.66)ng/ml of GBS patients shows higher serum level of IL-35 during the recovery phase than the serious subgroup(48.28±9.88)ng/ml.5.The axonal subgroup (463.62±92.00)pg/ml of GBS patients shows higher serum level of IL-17 during the acute phase than the demyelinating subgroup (412.75±77.12)pg/ml. However, the concentration of IL-35 in serum shows no significant difference between the axonal subgroup (40.90±7.77)ng/ml and demyelinating subgroup (42.95±10.61)ng/ml of GBS.6.The axonal subgroup (390.59±73.31)pg/ml of GBS patients shows higher serum level of IL-17 during the recovery phase than the demyelinating subgroup (352.53±58.67)pg/ml. However, the concentration of IL-35 in serum shows no significant difference between the axonal subgroup (52.25±10.09)ng/ml and demyelinating subgroup (53.28±13.38)ng/ml of GBS.Conclusion1.Our data indicates that IL-17 may play a role during the course of GBS, and it may act as a proinflammatory cytokine during the early effector phase of GBS.2.Our data indicates that IL-35 may play a role during the course of GBS, and it seems to have a distinct function in GBS as an attenuator of immune responses in the recovery phase.3.The higher serum level of IL-17 in the acute and recovery phase of GBS maybe positively related with the severity of symptoms,and the higher serum level of IL-35 in the recovery phase of GBS maybe correlates with the severity of symptoms negatively.4.Concentrations of IL-17 in serum during acute phase of GBS maybe related with the axonal subgroup pattern of GBS patients. |
PDF Full Text Request